Cryoport, Inc., a leading cryogenic logistics corporation, has secured a contract with an anonymous contract manufacturer to the biopharma industry to convert its current fleet of liquid nitrogen (N2) dewars to Cryoport’s comprehensive shipping solutions.
By adopting the US-based company’s programme, the unspecified client will use its Cryoport Express® Shippers and advanced SmartPakIITM Condition Monitoring Systems to ship its contract manufacturing biologics and cell therapy businesses.
These logistics means provide real-time conditions and location visibility with automated temperature deviation alerts, transit time deviations, LN2 hold time remaining, battery power levels and shipper orientation.
Jerrell Shelton, CEO of Cryoport, stated, “We have an offering that suits the needs of large and small companies in the life sciences industry and this latest customer win is a great example of how our solutions provide the best options for companies needing support in the vital area of temperature controlled logistics for the life sciences.”
Although the client remained unidentified, a press release indicated that it is a major supplier of product development services to the pharmaceutical and biologic industries, including custom manufacturing of biopharmaceuticals and services for the bioscience sector.